SAEVA Proceedings 2016 | Page 208

  been shown to have minimal adverse cardiovascular effects while the α-2 agonists have been shown to induce moderate to marked changes in heart rate, blood pressure and cardiac output in both adult horses and foals. In foals less than 2 weeks of age, diazepam generally provides excellent sedation and muscle relaxation and based on its cardiopulmonary effects, it is a logical first choice when a sedative is required. In older healthy foals, xylazine is recommended as it provides more reliable sedation, however, a benzodiazepine may be a suitable option in a critically ill foal greater than 2 weeks of age. Systemic administration of the opioid analgesic butorphanol is suitable for soft- tissue associated pain while morphine is an appropriate analgesic for orthopedic injuries. Optimizing analgesia in the equine patient is always a challenge due in large part to the side effects of the available analgesic agents. The inclusion of butorphanol (0.04 mg/kg) IV with either a benzodiazepine or an α-2 agonist improves the quality of analgesia and sedation of the latter agents with minimal adverse effects. Butorphanol can also be used on its own. The author favours giving to effect rather than to a timed dosing plan as absorption and duration of effect can be so variable. The administration of butorphanol as a CRI is well tolerated and it is a reliable adjunct in foals when prolonged sedation is required. Fentanyl patches are growing in their use, especially in small animal medicine and the author has had good experience with the use of fentanyl patches in neonates. The high lipid solubility of the mu agonist, ensures rapid transdermal uptake. The author aims for one 10mg patch per 150kg of body weight. One or two 2.5mg patches are placed on the foal (each releasing 25mcg/hr drug). These are replaced every 48-72 hours. Problems secondary to recumbency Entropion Hypoglycaemia Hypothermia Patent urachus Orthopaedic problems Decreased oxygen tensions Pressure sores/ulceration Gastric ulceration Mare rejection 15-­‐18  February  2016      East  London  Convention  Centre,  East  London,  South  Africa     207